18.06.2015 Views

Web-economic-crisis-health-systems-and-health-web

Web-economic-crisis-health-systems-and-health-web

Web-economic-crisis-health-systems-and-health-web

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Italy<br />

Francesca Ferrè <strong>and</strong> Walter Ricciardi<br />

Economic trends<br />

• Italy's real per capita GDP has been below the European average throughout<br />

the <strong>crisis</strong> period <strong>and</strong> growth was negative in both 2009 <strong>and</strong> 2010; real<br />

per capita GDP returned to low levels of growth in 2011. Italy has run a<br />

budget deficit in every year, including the years prior to the <strong>crisis</strong>.<br />

• Health spending as a share of government expenditure has remained<br />

constant <strong>and</strong> above the European mean. Growth of per capita public <strong>and</strong><br />

OOP expenditure on <strong>health</strong> were negative in 2010 but resumed positive<br />

growth in 2011 (Italy: Figs 1 <strong>and</strong> 2).<br />

Policy responses<br />

Changes to public funding for the <strong>health</strong> system<br />

• Extensive cuts to the <strong>health</strong> budget took place under the Financial Law<br />

(2011); further cuts (totalling €2.5 billion) were planned for 2012 to<br />

2014 (2012).<br />

• The government allocated additional resources to the <strong>health</strong> sector<br />

(€1.1 million in 2010, €400 million in 2011 <strong>and</strong> €300 million in 2012)<br />

as part of an central–regional government agreement to increase funding<br />

for the NHS, long-term care <strong>and</strong> social policy <strong>and</strong> to finance investments<br />

in public sanitary infrastructure (2010).<br />

Changes to <strong>health</strong> coverage<br />

Population (entitlement)<br />

• No response reported.<br />

The benefits package<br />

• Some regions reclassified drugs covered by the NHS (de-listing, price<br />

renegotiation within regional drug reference lists <strong>and</strong> setting maximum<br />

reimbursement limits when equivalent drugs become available); the<br />

main criteria for reclassification are clinical <strong>and</strong> cost–effectiveness, disease<br />

prevalence, drug's toxicity <strong>and</strong> drug's acceptance by patients) (since 2008).<br />

• Proposed adding services to the benefits package (treatment for 110 new<br />

rare diseases, chronic obstructive pulmonary disease, chronic osteomyelitis,

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!